论文部分内容阅读
卵巢癌的标准疗法对患者的不良顶后无多大改变。纽约斯隆·凯特林癌中心(MSKCC)采用创伤性外科和腹膜内给予顺铂,正着手于一项远大的、新的多学科研究,探索新的治疗方案。美国每年有18000名妇女患卵巢癌,死亡率很高,比子宫癌和宫颈癌患者死亡总数还多。卵巢癌已扩散后确诊的妇女,5年生存率为20～25％至10～15％。2/3以上患者为Ⅲ期和Ⅳ期癌,因为早期无症状,诊断技术也无进展。 MSKCC负责人William Hoskins说,由Avon制品基金会及私人资助的治疗卵巢癌
The standard therapy for ovarian cancer does not change much in patients with adverse top. The New York-based Sloane Kettering Cancer Center (MSKCC), with traumatic surgery and intraperitoneal administration of cisplatin, is embarking on an ambitious new multidisciplinary study to explore new treatment options. In the United States, 18,000 women suffer from ovarian cancer each year and have a high mortality rate, more than the total number of deaths from uterine and cervical cancer patients. Women who have been diagnosed with ovarian cancer have a 5-year 5-year survival of 20-25% to 10-15%. More than two-thirds of patients with stage III and IV cancer, as early as asymptomatic, no diagnostic technique. William Hoskins, director of MSKCC, said that Avon Products Foundation and privately funded treatment of ovarian cancer